Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy

Drugs

Volumn 60, Issue 6, 2000, Pages 1259-1287

  Tfelt Hansen, Peer ^a   De Vries, Petter ^b   Saxena, Pramod R ^b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; ELETRIPTAN; FROVATRIPTAN; RIZATRIPTAN; SEROTONIN 1B ANTAGONIST; SEROTONIN 1D ANTAGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

ANALGESIA; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HEADACHE; HEMODYNAMICS; HUMAN; MIGRAINE; NERVE BLOCK; REVIEW; SIDE EFFECT; TRIGEMINAL NERVE; VASOCONSTRICTION;

ANIMALS; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIGRAINE DISORDERS; MOLECULAR STRUCTURE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN; TRIGEMINAL NERVE;

EID: 0034524151     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060060-00003     Document Type: Review

References (206)

1. 1-like receptors: A time to bid goodbye
2. Pharmacology of triptans
3. Mode of action of the anti-migraine drug sumatriptan
4. Sumatriptan for the treatment of migraine attacks - A review of controlled clinical trials
5. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache
6. Methodology of clinical trials of sumatriptan in migraine and cluster headache
7. Migraine and cluster headache - Their management with sumatriptan: A critical review of the current clinical experience
8. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache
9. Sumatriptan. An updated review of its use in migraine
10. Twenty-four-hour effectiveness of BMS 180048 in the acute treatment of migraine headaches
11. Treatment of migraine with BMS 180048: Response at 2 hours
12. 1D agonist properties
13. Alniditan in the acute treatment of migraine attacks: A subcutaneous dose-finding study
14. 3H]alniditan
15. 1A receptors: Potential implications for prophylactic and acute therapy
16. 1B/1D receptor partial agonist, 311C90 (zolmitriptan)®
17. Naratriptan: Biological profile in animal models relevant to migraine
18. 1D receptors
19. Pharmacological profile of almotriptan, a novel antimigraine agent
20. 1D receptors
21. 1B receptors
22. 35S]GTPgammaS binding: Correlation with inhibition of guinea pig dural plasma protein extravasation
23. 7 receptor: Orphan found
24. 1 agonist, on the systemic, pulmonary, and coronary circulation
25. Transient additional effect of sumatriptan on ergotamine-induced constriction of peripheral arteries in man
26. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers
27. 1D agonist
28. 1D receptor antagonist
29. 1B/D receptor agonists in the normotensive rat
30. 1B/1D receptor agonist with anti-migraine activity
31. 1-like receptor agonist, GR43175
32. 1A receptor agonist flesinoxan with that of 8-OH-DPAT in the rat
33. Migraine pain associated with middle cerebral artery dilatation: Reversal by sumatriptan
34. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks
35. Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine
36. 1B/1D receptor partial agonist for the acute treatment of migraine
37. 1D receptor agonist MK-462
38. 1D-like" receptors
39. (1B/1D) receptor agonist, SB 209509 (VML251), and sumatriptan in dogs
40. Lack of effect of MK-462 on cerebral blood flow in humans
41. 1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses
42. Pathogenesis of migraine
43. Cranial arteriovenous shunting, an in vivo animal model for migraine
44. Assessment of peripheral vascular effects of antimigraine drugs in humans
45. (1B/1D) receptor ligand frovatriptan in human isolated basilar and coronary arteries
46. 1D agonist drugs: Selectively targeting additional sites of action
47. Further characterization of the in vitro pharmacology of eletriptan
48. Rizatriptan selectively contracts human middle meningeal over coronary artery: Comparison with sumatriptan
49. Human middle meningeal and coronary artery contraction to eletriptan and sumatriptan
50. Pharmacological analysis of contraction to eletriptan and sumatriptan in human isolated coronary artery and saphenous vein
51. 1D-like" receptor in the dog saphenous vein
52. 1D receptor agonist MK-462
53. Coronary side-effect potential of current and prospective antimigraine drugs
54. 1D receptor agonists and human coronary artery reactivity in vitro: Cross-over comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519
55. 2 receptor activation
56. 5-HT receptors mediating contractions of the isolated human coronary artery
57. 1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats
58. The novel antimigraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation
59. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats
60. 1D receptor agonist 311C90
61. 1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats
62. 1B/D receptor agonist zolmitriptan (311C90): Are brain stem sites therapeutic target in migraine?
63. 1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats
64. 1B/1D) receptors
65. Rizatriptan has central antinociceptive effects against durally evoked responses
66. 1B receptors
67. 1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater
68. 1F receptors: Binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine
69. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs
70. CP-122,287 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: Results of two controlled clinical trials
71. Retinal plasma extravasation in animals but not in humans: Implications for the pathophysiology of migraine
72. 3H]311C90 binding sites in cat brain stem: Implications for migraine treatment
73. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine
74. Current concepts of the pathophysiology of migraine
75. 1B/1D receptor agonists in the acute treatment of migraine
76. 1-like receptor agonists and the pathophysiology of migraine
77. Clinical and experimental effects of sumatriptan in humans
78. The mode of action of sumatriptan is vascular? A debate
79. Neural processing of craniovascular pain: A synthesis of the central structures involved in migraine
80. 1D agonist
81. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan
82. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration
83. Single dose pharmacokinetics of sumatriptan in healthy volunteers
84. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers
85. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers
86. 1B/1D agonist zolmitriptan in healthy young and elderly men and women
87. Oral naratriptan (2.5-10 mg) exhibit dose-proportional pharmacokinetics
88. A study to determine the absolute oral bioavailability of naratriptan
89. Rizatriptan, a novel 5-HT1B/1D agonist for migraine: Single- and multiple-dose tolerability and pharmacokinetics in healthy subjects
90. Pharmacokinetics and food interaction of MK-462 in healthy males
91. The pharmacokinetics, safety and tolerability of oral eletriptan in subjects with impaired hepatic function
92. In vitro metabolism of eletriptan in human liver microsomes
93. Comparative absorption and elimination of eletriptan in rat, dog and human
94. Electrocardiographic effects and phannacokinetics of oral almotriptan in healthy subjects
95. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug
96. Oral almotriptan in the treatment of migraine. A dose finding study
97. 1B/1D agonist, following single dose administration by oral and intravenous routes to healthy male and female volunteers
98. 1D-like agonists as a predictor of oral absoption potential
99. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses
100. 1D agonist 311C90
101. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers
102. Zolmitriptan: A new acute treatment for migraine
103. A study to investigate the potential interaction of naratriptan and ergotamine
104. A study to investigate the potential interaction of naratriptan and dihydroetgotamine
105. 1B/1D receptor agonist for the treatment of migraine
106. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine
107. Comparison of the efficacy of zolmitriptan and sumatriptan: Issues in migraine trial design
108. Comparison of zolmitriptan and sumatriptan for the acute treatment of migraine
109. Comparison of rizatriptan 10 mg versus zolmitriptan 2.5 mg in migraine
110. Efficacy of naratriptan tablets in the acute treatment of migraine: A dose-ranging study: Naratriptan S2WB2004 study group
111. Efficacy and tolerability of naratriptan tablets (0.1-2.5 mg) in the acute treatment of migraine
112. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients; Naratriptan international recurrence study group
113. Comparison of rizatriptan 10 mg vs naratriptan 2.5 mg in migraine
114. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study
115. Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine
116. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine
117. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine
118. Clinical measures of efficacy, safety and tolerability for the acute treatment of migraine: A comparison of eletriptan (20-80 mg), sumatriptan (100 mg) and placebo
119. Comparison of the efficacy of oral eletriptan and oral sumatriptan for the acute treatment of migraine: Combined analysis across three clinical trials
120. 1B/1D agonist, compared with sumatriptan 100 mg
121. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: A dose-ranging study
122. A randomized, double-blind comparison of sumatriptan in the acute treatment of migraine
123. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine
124. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine
125. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel-group study
126. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo
127. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine
128. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine
129. Efficacy and safety of intravenous acerylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, parallel group study
130. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine
131. Comparison of the efficacy, safety and tolerability of oral eletriptan and Cafergot® for the acute treatment of migraine
132. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systemic review based on number needed to treat
133. Treatment of acute migraine with subcutaneous sumatriptan
134. Treatment of migraine attacks with sumatriptan
135. Self-treatment of acute migraine with subcutaneous sumatriptan using an autoinjector device
136. Sumatriptan in acute migraine using a novel cartridge system self-injector
137. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice
138. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: A placebo-controlled study
139. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis
140. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine
141. A randomized, double-blind, placebo-controlled crossover study of subcutaneous sumatriptan in general practice
142. The efficacy and safety of sumatriptan in the acute treatment of menstrual migraine
143. Efficacy and tolerability of of subcutaneous sumatriptan administered using the IMITREX®_STATdose™ system
144. Sumatriptan injection reduces productivity loss during a migraine attack. Results of a double-blind, placebo-controlled trial
145. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: A multicenter study
146. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine
147. Efficacy and safety of sumatriptan tablets (25mg, 50mg, 100mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan
148. Sumatriptan - An oral dose-defining study
149. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine
150. Oral sumatriptan in acute migraine
151. Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths
152. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: Results of a multicenter study
153. Oral sumatriptan compared with placebo in the acute treatment of migraine
154. Oral sumatriptan for the long-term treatment of migraine: Clinical findings
155. A double-blind placebo-controlled study assessing the efficacy and tolerability of sumatriptan 50-mg tablets in the acute treatment of migraine
156. Patients preference for oral sumatriptan 25, 50 or 100 mg in the acute treatment of migraine: A double-blind, randomized, crossover study
157. Intranasal sumatriptan for the acute treatment of migraine
158. Sumatriptan nasal spray: A review of data from multinational clinical trials
159. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies
160. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine
161. Sumatriptan nasal spray: A dose-ranging study in the acute treatment of migraine
162. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types
163. Sumatriptan suppositories for the acute treatment of migraine
164. A placebo-controlled, dose-defining study of sumatriptan suppositories in the acute treatment of migraine
165. Safety and efficacy of sumatriptan suppositories in the acute treatment of migraine attacks
166. Safety and efficacy of sumatriptan suppositories in the acute treatment of migraine attacks
167. Oral sumatriptan: Effect of a second dose, and treatment of headache recurrence
168. Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice
169. Sumatriptan in clinical practice: A 2-year review of 453 migraine patients
170. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan
171. The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache
172. Subcutaneous sumatriptan during migraine aura
173. 1B/1Dagonist: An overview of efficacy
174. 311C90: Increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists
175. The clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine
176. 311C90, a new central and peripherally acting 5-HTiD receptor agonist in the acute oral treatment of migraine: A double-blind, placebo-controlled, dose-range finding study
177. Optimizing the dose of zolmitriptan (ZomigTM, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study
178. Zolmitriptan, a 5-HT receptor agonist for the acute oral treatment of migraine: A multicentre, dose-range finding study
179. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled crossover study
180. Naratriptan is effective and well-tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study
181. Naratriptan
182. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine
183. Rizatriptan (MAXALT®) for the acute treatment of migraine and migraine recurrence
184. A placebo-controlled crossover study of rizatriptan in the treatment of multiple attacks
185. Rizatriptan RPD™ for the acute treatment of migraine
186. A dose-finding study of eletriptan (UK-116,044) (5-30 mg) for the acute treatment of migraine
187. Efficacy, safety and tolerability of oral eletriptan versus placebo in the acute treatment of migraine: A phase III randomised trial
188. Adverse event profile of oral eletriptan: Review of clinical trial experience
189. 1Dagonist
190. Meta-analysis of the efficacy and safety of almotriptan in the treatment of migraine
191. 1B/1D agonist
192. 1B/1D agonist for the treatment of migraine attacks
193. 1B/1Dagonist for the treatment of migraine
194. Long-term experience with sumatriptan in the treatment of migraine
195. Long-term efficacy of subcutaneous sumatriptan using a novel self-injector
196. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study
197. The tolerability and efficacy of naratriptan tablets with long-term treatment (6 months)
198. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine
199. Pitfalls in long-term studies assessing acute migraine therapy
200. Verbal scales in the acute treatment of migraine: Semantic categories and clinical relevance
201. How to assess and compare drugs in the management of migraine: Success rates in term of response and recurrence
202. The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: Methodological aspects and time effect curve
203. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration
204. Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders?